Tami Swenson serves as a Study Director at Labcorp Drug Development in Madison, WI, where she plays a pivotal role in the GLP and non-GLP preclinical safety assessment of pharmaceutical studies. With a robust academic background in environmental chemistry, microbiology, biochemistry, and toxicology, Tami brings...
Tami Swenson serves as a Study Director at Labcorp Drug Development in Madison, WI, where she plays a pivotal role in the GLP and non-GLP preclinical safety assessment of pharmaceutical studies. With a robust academic background in environmental chemistry, microbiology, biochemistry, and toxicology, Tami brings a wealth of knowledge to her position. Her specialized expertise in mass spectrometry-based metabolomics enables her to conduct comprehensive analyses that are critical for understanding the safety profiles of new drug candidates.
In her current role, Tami oversees a variety of key projects that involve the design and execution of preclinical studies aimed at evaluating the safety and efficacy of pharmaceutical compounds. Her responsibilities include managing study protocols, ensuring compliance with regulatory standards, and leading cross-functional teams to deliver high-quality data. Tami's proficiency in advanced techniques such as Liquid Chromatography-Mass Spectrometry (LC-MS) and in vitro methodologies enhances her ability to interpret complex data sets and draw meaningful conclusions that inform drug development processes.
Tami is also adept in molecular biology and organic chemistry, skills that are essential for the synthesis and analysis of compounds during preclinical assessments. Her commitment to data integrity and scientific rigor not only supports Labcorp's mission to advance healthcare but also positions her as a trusted leader in the field of drug development. As she continues to drive innovative research initiatives, Tami remains dedicated to contributing to the safety and efficacy of new therapeutics, ultimately improving patient outcomes.
